Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

about

Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

Item

http://www.wikidata.org/entity/Q35638905

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Variations in erythropoiesis-s ...... tic syndromes impact response.

@ast

Variations in erythropoiesis-s ...... tic syndromes impact response.

@en

type

Item

label

Variations in erythropoiesis-s ...... tic syndromes impact response.

@ast

Variations in erythropoiesis-s ...... tic syndromes impact response.

@en

prefLabel

Variations in erythropoiesis-s ...... tic syndromes impact response.

@ast

Variations in erythropoiesis-s ...... tic syndromes impact response.

@en

P1476

Variations in erythropoiesis-s ...... tic syndromes impact response.

@en

P2093

Amer M Zeidan

http://www.w3.org/2001/XMLSchema#string

Franklin Hendrick

http://www.w3.org/2001/XMLSchema#string

Maria R Baer

http://www.w3.org/2001/XMLSchema#string

Masayo Sato

http://www.w3.org/2001/XMLSchema#string

Sheila R Weiss

http://www.w3.org/2001/XMLSchema#string

Steven D Gore

http://www.w3.org/2001/XMLSchema#string

Vu H Duong

http://www.w3.org/2001/XMLSchema#string

P2860

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.

A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes

Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.

The myelodysplastic syndromes: diagnosis and treatment.

Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes.

Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.

P304

586-591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LEUKRES.2015.03.013

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Amy J Davidoff

P577

2015-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25869077

http://www.w3.org/2001/XMLSchema#string

P932

4441842

http://www.w3.org/2001/XMLSchema#string